- Oral presentation
- Open Access
Specificity of commonly used cyclic nucleotides with PKA, PKG and Epac-implementing microcalorimetry to determine PDE activities
© Beavo et al; licensee BioMed Central Ltd. 2007
- Published: 25 July 2007
- Cyclic Nucleotide
- Guanine Nucleotide Exchange Factor
- Nucleotide Analogue
- High Inhibitory Effect
Two main structural classes of cyclic nucleotide receptors exist in mammalian cells. The first class contains a conserved cyclic nucleotide binding (CNB) domain, found in the regulatory regions of PKG and PKA in cyclic nucleotide regulated ion channels and in Epac. The second class contains a GAF domain that can bind cyclic nucleotides but is structurally unrelated to CNB domains. GAF domains are present in some phosphodiesterases (PDEs) allosterically regulated by cyclic nucleotides. In addition, cGMP and cAMP are bound and hydrolysed by PDEs at their catalytic site.
The important feature of this work was to measure 12 of the most commonly used cyclic nucleotide analogues on protein kinase A I and II (PKA I and II), protein kinase G Iα, Iβ and II (PKG Iα, Iβ and II), and the guanine nucleotide exchange factor Epac I. The study is extended to eight cyclic nucleotide hydrolysing phosphodiesterases (PDE IA, IB, IC, II, IV, V, VI and X), thereby introducing microcalorimetry to overcome radioactive labeling of the tested analogs and allowing analysis of the kinetic parameters Km, Ki and Vmax .
We successfully used isothermal titration microcalorimetry (ITC) for analysing the kinetic parameters of eight PDEs by various cAMP- and cGMP-analogs. The measured data reflect very well the reported literature and the technique offers significant advantages over traditional microbiological methods. The measuring of both, kcat and Km, provide additional insight into protein active sites by determining competitive, non-competitive and linear-mixed inhibition of the PDEs by the cyclic nucleotides.
To our surprise, some accepted hydrolysis-stable analogs became degraded by the newer phosphodiesterases or show high inhibitory effects. As an example, we show side effects of an Epac specific activator on platelet signalling pathways.
The defined specificity profiles of the tested cyclic nucleotides are presented in clearly arranged tables and will help to interpret in vivo data in the light of the cyclic nucleotide receptor proteins present in a given cell.
An extended overview of the data will be accessible to the scientific community at: http://www.cyclic-nucleotides.net after publication.
This article is published under license to BioMed Central Ltd.